An interventional study of electro-stimulation suit and Usual Care in Multiple Sclerosis, MS (Multiple Sclerosis) and Spasticity With Multiple Sclerosis, sponsored by Daphne Kos. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Daphne Kos · Not applicable, Interventional, and Supportive care
This study is being carried out at Multiple Sclerosis (MS) centers to evaluate whether a full-body stimulation suit at home can help people with Multiple Sclerosis (pwMS) reduce symptoms like spasticity (muscle stiffness) and ataxia (poor coordination), and improve daily functioning.
Can pwMS who experience spasticity or ataxia benefit from using a stimulation suit for 6 weeks?
Researchers will compare two groups: an intervention group (who will use the suit) and a control group (who will not use the suit).
Participants in the intervention group will:
Participants in the control group will:
3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.
This study's planned enrollment of 70 is above the median of 50 across 2,201 interventional studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →This is the only study on the registry with Daphne Kos as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will wear a full-body stimulation suit every day or every other day for six weeks, in addition to their usual care.
Device: electro-stimulation suit · Other: Usual Care
This group will be a comparator and have no added intervention expect for their usual care.
Other: Usual Care
In EXOPULSE Mollii Suit is a multi-channel full-body suit with a low energy electrical stimulation - 20 Volt and 20 Hz. It generates 2 milliamp pulses (into 0-10,000 Ohms) with the following parameters: * Pulse width: variable between 25 and 170 μs. * Length of period: 50 ms. * Maximum amplitude: 20 V. It is composed of a control unit, a jacket and pants, with 58 embed-ded electrodes, in direct contact with the skin, and pre-positioned to stimulate 40 key muscle groups. The suit comes in different sizes. A trained medical staff pre-programs which nerves/muscles to be stimulated based on a clinical assessment of the user and the outcome is evaluated through standardized methods. The stimulation program is thus specific to each user.
Also known as: neuromodulation suit, stimulation suit, EXOPULSE MOLLII suit
The rehabilitation therapy that is being offered at the National MS Center Melsbroek, but somewhat reduced/adjusted to make time for initiation and follow-up of using the neuromodulation suit and potentially also during the weeks at home (i.e., rehabilitation being offered by municipalities).
Also known as: standard care
NHPT+SSST score
The primary outcome will be a combined measure of upper and lower extremity motor function, consisting of the Nine Hole Peg Test and the Six Spot step test (labelled NHPT+SSST score). Values are expressed in seconds. A higher score, indicates a worse outcome.
Time frame: After one and six weeks of stimulation for the intervention group. The control group will be assessed at the same time points.
Six spot step test (SSST)
Similar to the T25FW, the SSST is a quantitative measure of lower extremity function. The test contains a rectangular field with six circles on the floor following a criss-cross course. Five circles contain a block. The starting-point is the first circle, which does not contain a block. From there the patient walks to the other side of the field and kicks the blocks out of the five circles, as quickly as possible. The task is immediately administered again by having the patient walk back the same route. Both the dominant and non-dominant legs are tested twice. The Maximum value: 300.0 seconds A higher score indicates a worse outcome.
Time frame: SSST assessment will take place after weeks 1 and 6 of stimulation.
Nine Hole Peg Test (NHPT)
The Nine-Hole Peg Test (NHPT) is an assessment tool used to evaluate movement speed, particularly fine hand motor skills. The patient must take nine pegs from a container as quickly as possible and place them into the holes on a board. Afterwards, the patient must remove the pegs and return them to the container. The time taken to complete the task is measured. The patient may only use the hand being tested and must repeat the procedure for each peg individually (they are not allowed to pick up multiple pegs at once). A higher score indicates a worse outcome.
Time frame: NHPT assessment will take place after weeks 1 and 6 of stimulation.
Modified Ashworth Scale (MAS)
The Modified Ashworth Scale (MAS) is designed to objectively assess the degree of spasticity. The MAS measures the level of hypertonia in the left and right elbows and knees. The therapist evaluates the muscle tone and records the highest level of tone felt during five repetitions per joint, using a six-point scale (0 = no increase in muscle tone, 4 = limb rigid in flexion or extension and cannot be moved). A higher score indicates a worse outcome.
Time frame: MAS assessment will take place during screening, as they are used to determine eligibility and after weeks 1 and 6 of stimulation.
Scale for the Assessment and Rating of Ataxia (SARA)
SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test. The minimum value: 0 The maximum value: 40 A higher score indicates a worse outcome.
Time frame: SARA assessment will take place during screening, as they are used to determine eligibility and after weeks 1 and 6 of stimulation.
Numeric Rating Scale (NRS)
The severity of ataxia and spasticity will be documented bij a numeric scale. The minimum value: 0 The maximum value: 10 A higher score indicates a worse outcome.
Time frame: NRS assessments will take place after weeks 1 and 6 of stimulation.
6 Minute walk test
The goal is for the participant to walk as many meters as possible within 6 minutes over a 30-meter course. The participant may use walking aids or foot orthoses. This test assesses the participant's functional capacity. The more meters walked, the better the functional capacity.
Time frame: The assessment will take place after weeks 1 and 6 of stimulation.
5 times sit to stand test (5STS)
De Timed Chair Stand Test is a simple evaluative test used to assess, among other things, muscle strength, balance, and fall risk in older adults. During the Timed Chair Stand Test, the patient is asked to stand up from a chair and sit down again five times as quickly as possible, without using the arms. The physiotherapist records the time in seconds. A score greater than 14s indicates a fall risk.
Time frame: The assessment will take place after weeks 1 and 6 of stimulation.
The patient-Determined Disease Steps (PDDS)
A questionnaire on how a person with MS preceives their capacity to walk. The patient needs to chose one descrition the reflects their condition the best. The minimum value: 0 The maximum value: 8 A higher score, indicates a worse outcome.
Time frame: PDDS assessment will take place after weeks 1 and 6 of stimulation.
The 12-item Multiple Sclerosis Walking Scale (MSWS12)
The 12-item Multiple Sclerosis Walking Scale (MSWS-12) is a self-report measure of the impact of MS on the individual's walking ability. The minimum value: 0 The maximum value: 100 A higher score, indicate a worse outcome.
Time frame: MSWS-12 assessment will take place after weeks 1 and 6 of stimulation.
The 36-item Manual Ability Measurement (MAM36)
The Manual Ability Measure (MAM) is designed as an outcome instrument to assess hand function based on the patient's responses to functional questions. Tasks are rated on a scale from 0 (cannot be done) to 4 (easy to do). Total scores range from 0 to 144. A higher score indicates greater perceived manual ability.
Time frame: MAM36 assessment will take place after weeks 1 and 6 of stimulation.
The EuroQol Questionnaire (EQ-D5)
The EQ-5D is a standardized instrument that provides a score across five health dimensions: mobility, self-care, daily activities, pain/discomfort, and anxiety/depression. (5 items, three or five response categories) In addition, the patient must indicate how they perceive their overall health status on a scale from 0 to 100. To interpret the results correctly, it is important that the healthcare provider is familiar with the patient's demographic information. (8 items) A higher score indicates a worse outcome.
Time frame: EQ-5D assessment will take place after weeks 1 and 6 of stimulation.
adapted Treatment Satisfaction Questionnaire for Medication version 1.4 (TSQM 1.4)
Is used to evaluate treatment satisfaction with the particular aim of development and evaluation of treatment satisfaction among the patients already undergoing treatment. TSQM (1.4) has 14 questions divided into 4 subscales: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). Higher scores indicate a higher patient satisfaction with medication (Liberato et al. 2020). The questions have been re-formulated so they are applicable to using the stimulation suit.
Time frame: The adapted TSQM 1.4 assessment will take place after weeks 1 and 6 of stimulation. Only for the intervention group
SymptoMScreen
A tool for rapid assessment of MS symptom ( the six most common areas where symptomatic complaints occur and are discussed during clinical visits) severity in routine clinical practice. It uses a 7-point Likert scales for each functional domain (0 = not affected at all, 6 = total limitation/I'm unable to do most daily activities). The minimum value: 0 The maximum value: 72 A higher score indicates a worse outcome.
Time frame: SymptoMScreen assessment will take place weekly from the start of the intervention until end of the study.
Modified Fatigue Impact Scales (MFIS)
The assessment will be used to assess the physical, cognitive, and psychosocial impact of fatigue. Each of the 21 items of the MFIS will be scored from 0-to-4, providing a total score ranging from 0 to 84 (higher scores, greater fatigue impact).
Time frame: The assessment will take place after weeks 1 and 6 of stimulation.
Multiple Sclerosis (MS) type
MS type: primary progressive (PP), secundary progressive (SP), relapsing remitting (RR), ..
Time frame: Will be collected (at baseline) when a partcipant is found eligible
age
Age (years)
Time frame: Will be collected at baseline when a partcipant is found eligible
sex
sex (m/v)
Time frame: Will be collected at baseline when a partcipant is found eligible
height
height (cm)
Time frame: Will be collected at baseline when a partcipant is found eligible
weight
weight (kg),
Time frame: Will be collected at baseline when a partcipant is found eligible
Expanded Disability Status Score (EDSS)
latest EDSS: The Expanded Disability Status Scale measures your current level of disability. Values: (0.0 -10.0) A higher score indicates a worse outcome
Time frame: Will be collected (at baseline) when a partcipant is found eligible
Time since diagnosis
time since diagnosis (years)
Time frame: Will be collected (at baseline) when a partcipant is found eligible
Medication
Previous and current MS medication. previous and current ataxia or spasticity medication will be listed
Time frame: Will be collected (at baseline) when a partcipant is found eligible
Onset Spasticity and/or ataxia
Time since onset of ataxia or spasticity. (years)
Time frame: Will be collected (at baseline) when a partcipant is found eligible
Comorbidities
Comorbidities will be listed.
Time frame: Will be collected (at baseline) when a partcipant is found eligible
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Sep 2027, 18 months after the start.
Of 847 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's planned 18 months is below that.
Counting every sponsor, half of 869 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.